18F-FDG PET/CT评估三阴性乳腺癌新辅助化疗疗效的研究进展

Advances of assessment with 18F-FDG PET/CT in triple-negative breast cancer during neoadjuvant chemotherapy

  • 摘要: 三阴性乳腺癌(TNBC)是一种雌激素受体(ER)、孕激素受体(PR)及人表皮生长因子受体2(HER-2)表达均为阴性的乳腺癌亚型,常发生于绝经前的女性,具有预后较差、5年生存率低、侵袭性强、易复发及发生远处转移等特征。目前TNBC主要的治疗方法是手术与化疗,其中新辅助化疗的应用也越来越广泛。近年来,18F-FDG PET/CT在乳腺癌治疗评估中的价值已被广泛研究,PET/CT监测乳腺癌新辅助化疗疗效的价值已得到肯定。该文对18F-FDG PET/CT评估TNBC新辅助化疗疗效的研究进展进行综述。

     

    Abstract: Triple-negative breast cancer(TNBC)is a distinctive sub-group of breast cancers that do not express estrogen receptors(ER), progesterone receptors(PR) and human epidermal growth factor receptor 2(HER2). TNBC often happens to premenopausal women, and having special features such as poor prognosis, short 5-year survival, strong tumor invasion, high incidence of local recurrence and distant metastasis. Chemotherapy and surgery are mainly available systemic treatments of TNBC, and neoadjuvant chemotherapy(NAC)has become a widely used systemic treatment. Recently, the value of 18F-FDG PET/CT in breast cancer has been extensively studied, the role of PET/CT monitoring the efficacy of NAC has been a positive result. In this paper, the research progress of assessment with 18F-FDG PET/CT in TNBC during neoadjuvant chemotherapy was reviewed.

     

/

返回文章
返回